Ocular Therapeutix, Inc.

As of October 3, 2025, Ocular Therapeutix, Inc. shows a mildly bullish trend with mixed technical indicators, having underperformed the S&P 500 recently but outperformed it year-to-date.

As of October 3, 2025, Ocular Therapeutix, Inc. shows a mildly bullish trend with mixed signals from indicators, having underperformed the S&P 500 recently but outperformed it year-to-date and over the past year.

As of October 3, 2025, Ocular Therapeutix, Inc. shows a mildly bullish technical trend with mixed signals across indicators, having underperformed the S&P 500 recently but outperformed it year-to-date and over the past year.

As of September 19, 2025, Ocular Therapeutix, Inc. shows a mildly bullish trend with strong MACD and Bollinger Bands indicators, having returned 42.86% year-to-date, significantly outperforming the S&P 500's 13.31%.

As of September 19, 2025, Ocular Therapeutix, Inc. has a mildly bullish technical outlook, supported by positive MACD readings and moving averages, despite mixed signals from KST and RSI, while outperforming the S&P 500 year-to-date and over the past year.

As of July 17, 2025, Ocular Therapeutix, Inc. has a bullish technical trend, outperforming the S&P 500 with a year-to-date return of 48.83% compared to 12.22%, supported by bullish MACD indicators and moving averages.

As of June 18, 2025, the market trend is neutral with mixed signals; while weekly MACD and RSI are bullish, monthly indicators suggest caution, resulting in a balanced outlook.

As of March 2022, the management team of Ocular Therapeutix, Inc. includes Mr. Charles Warden (Independent Chairman), Mr. Antony Mattessich (President and CEO), and several independent directors: Dr. Jeffrey Heier, Dr. Richard Lindstrom, Mr. Bruce Peacock, Dr. Suh Hong Seung, and Ms. Leslie Williams. They oversee the company's strategic direction and operations.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing therapies for eye diseases, with a market cap of approximately $1.32 billion. As of March 2025, it reported net sales of $11 million and a net loss of $64 million.

As of Jun 18, Ocular Therapeutix, Inc. has a market capitalization of $1.32 billion, with net sales of $59.65 million and a net profit of -$192.71 million over the latest four quarters.